India Pharma Outlook Team | Tuesday, 11 November 2025
Torrent Pharmaceuticals, the flagship company of the Torrent Group, Ahmedabad, is leading its next phase of growth through innovative chronic therapies and expansion in the emerging areas with high growth such as weight loss treatments.
As the company, a market leader in the vitamins segment with its Rs 500-crore brand Shelcal and cardiac drug Nikoran with Rs 245-crore in sales, plans to strengthen these core segments while venturing into new therapeutic frontiers.
According to the Managing Director, Aman Mehta, Torrent's future strategy is based on the idea of the company solving the unmet needs of chronic disease management by way of R&D-driven innovation. Apart from India, he also mentioned that Brazil is going to be the largest international market of the company, followed by the US and Germany.
If an opportunity for setting up a manufacturing plant in the US comes with a long-term strategic value, especially in complex product segments that are less affected by price pressure, the company will be willing to do so.
Also Read: CDSCO Clears MSN Labs' Abiraterone 1000mg for Phase IV Trial
Torrent has just finished the purchase of one of its most important acquisitions — JB Chemicals & Pharmaceuticals — indicating a significant milestone in its growth journey. The acquisition, which was funded through worldwide debt financing to the tune of Rs 12,000 crore, is in line with Torrent's acquisition-led expansion strategy, thus, after the earlier takeovers of Elder Pharma, Unichem, and Curatio.
In the future, Torrent wants to keep the ball rolling with the innovation-led growth strategy by creating a strong pipeline of first-to-market products both in India and Brazil. Also, the company plans to strengthen its global presence through the strategic investments as well as partnership
